ADVERTISEMENT

Muntinlupa prepares to register 12 to 17-year-olds for COVID-19 vaccination

Published Sep 11, 2021 12:03 pm

Muntinlupa Mayor Jaime Fresnedi said the city government is preparing to start the registration of adolescents aged 12 to 17 years old for vaccination against coronavirus disease (COVID-19).

The registration will be handled by the Muntinlupa City COVID-19 Vaccination Program team, which currently supervises the inoculation of residents and essential workers.

Muntinlupa Mayor Jaime Fresnedi talks to a resident who is getting her shot at the SM Center Muntinlupa vaccination site Saturday (Muntinlupa PIO)

The move follows other local government units (LGUs), which have opened the registration for the age group.

As of Sept. 8, 192,360 individuals have been fully vaccinated in Muntinlupa or 49.9 percent of the target population of 385,725.

A total of 319,963 individuals received their first dose or 83 percent of the target population. The tally included 11,404 individuals who were vaccinated in Muntinlupa private companies.

According to MunCoVac, 507,964 vaccine doses were administered as of Sept. 8 since the city started its vaccination program in March.

Last Sept. 2, the country’s Food and Drug Administration (FDA) approved the use of the Moderna vaccine for 12 years and above.

This after Zuellig Pharma Corp. requested FDA to amend the original Emergency Use Authorization (EUA) dated Aug. 12, which allowed Modern to be used for 18 years old and above.

“This applies to the request to amend the Emergency Use Authorization dated 12 August 2021 for the COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) Dispersion for Injection (I.M.) (COVID-19 Vaccine Moderna) to expand the therapeutic indication to 12 years of age and older. After due consideration, the Food and Drug Administration (FDA) hereby revises the EUA granted to COVID-19 Vaccine Moderna as requested,” the FDA told Zuellig Pharma in a letter.

The FDA approved the use of Modern for at least 12 years old “based on the totality of evidence available to date, including data from adequate and well- known controlled trials, it is reasonable to believe that the COVID-19 Vaccine Moderna may be effective to prevent, diagnose, or treat COVID-1.”

“The known and potential benefits of the COVID-19 Vaccine Moderna, when used to diagnose, prevent or treat COVID-19, outweigh the known and potential risks of said Vaccine as of date; and there is currently no adequate, approved and available alternative to the product for diagnosing, preventing or treating COVID-19,” the FDA added.

According to the FDA, the Moderna vaccine is a two-dose vaccine with the second dose administered after 28 days.

Related Tags

MunCoVac Muntinlupa Muntinlupa vaccination 12 to 17 years old vaccination covid-19 vaccination program MODERNA VACCINE
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ articles_filter_1564_widget.title }}

.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });

Sign up by email to receive news.